Mylan Puts Its Troubles in the Past, at a Price of $465 Million

  • Settlement ‘gets the U.S. government out of Mylan’s hair’
  • Shares gain on Monday morning following Friday deal with U.S.

Heather Bresch, chief executive officer of Mylan NV, arrives to a House Oversight and Government Reform Committee hearing in Washington, D.C., on Sept. 21, 2016.

Photographer: Andrew Harrer/Bloomberg

The worst appears to be over for Mylan NV and its EpiPen controversy. It took a $465 million settlement with the U.S. Justice Department and a grilling from Congress for its chief executive officer to get there.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.